Diabetes requiring insulin tied to increased stroke risk in A-fib

January 26, 2017

(HealthDay)—For patients with atrial fibrillation (AF), diabetes requiring insulin, but not diabetes without insulin treatment, is associated with an increased risk of stroke/systemic embolism, according to a study published in the Jan. 31 issue of the Journal of the American College of Cardiology.

Giuseppe Patti, M.D., from the Campus Bio-Medico University of Rome, and colleagues examined the differential role of insulin versus no on thromboembolic risk in a cohort of with AF. The authors compared the rates of stroke/systemic embolism at one year according to status. Data were included for 5,717 patients; 1,288 of these had diabetes, of whom 22.4 percent were on insulin.

The researchers found that the risk of stroke/systemic embolism at one year was increased for patients with diabetes who were on insulin, compared to those without diabetes (5.2 versus 1.9 percent; hazard ratio, 2.89; 95 percent confidence interval, 1.67 to 5.02; P = 0.0002) or those with diabetes without (5.2 versus 1.8 percent; hazard ratio, 2.96; 95 percent confidence interval, 1.49 to 5.87; P = 0.0019). Similar rates of stroke/embolism were seen for patients with diabetes not receiving insulin and for patients without diabetes (hazard ratio, 0.97; 95 percent confidence interval, 0.58 to 1.61; P = 0.90).

"In this cohort of anticoagulated patients with AF, the sole presence of diabetes not requiring insulin did not imply an increased thromboembolic risk," the authors write. "Conversely, -requiring diabetes contributed most, if not exclusively, to the overall increase of thromboembolic risk in AF."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Long-acting analog insulin doesn't up AMI risk in T2DM

More information: Full Text
Editorial

Related Stories

Long-acting analog insulin doesn't up AMI risk in T2DM

August 20, 2015

(HealthDay)—For patients with type 2 diabetes, the risk of acute myocardial infarction (AMI) is not significantly different for long-acting insulin analogs versus other basal insulin therapies, according to a study published ...

Lowest glucose variability for insulin + GLP-1 RA in T2DM

December 20, 2016

(HealthDay)—For patients with type 2 diabetes, the lowest glucose variability (GV) and hypoglycemia is seen for patients using basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), according to a study ...

CVD risk similar for metformin + insulin or sulfonylureas

July 20, 2015

(HealthDay)—For patients with type 2 diabetes, the risk of myocardial infarction (MI) or stroke is similar for treatment with insulin or sulfonylureas in combination with metformin, according to a study published online ...

Recommended for you

Many diabetes patients produce some insulin

June 22, 2017

Some insulin is still produced in almost half of patients that have had type 1 diabetes for more than ten years. The study conducted by researchers at Uppsala University in Sweden has now been published online by the medical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.